🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

20 recruiting trials

for IgG4-Related Disease

National Registry of IgG4-RD in China NCT03023371n/a1 site📍 Beijing Peking Union Medical College Hospital A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease NCT07068165Phase 2, Phase 31 site📍 Beijing Peking Union Medical College Hospital · Tests: 5mg lenalidomide, 10mg lenalidomide, Prednisone monotherapy BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases NCT06794008Phase 21 site📍 Beijing Peking University People's Hospital · Tests: BCMA-CD19 CAR-T therapy A Study on the Effect of MRD Detected by FAPI PET / CT on the Recurrence of IgG4-RD NCT07104058NA1 site📍 Beijing Luo Yaping · Tests: 68Ga-FAPI PET / CT A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases NCT06978647Phase 11 site📍 Beijing China Immunotech (Beijing) Biotechnology Co., Ltd. · Tests: YTS109 cell Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497361EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: PRG-2311 Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease NCT07148791Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: Anti-BCMA-CD19 CAR-T cells Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease NCT07061938Phase 1, Phase 211 sites📍 Atlanta📍 Boston📍 Beijing Acepodia Biotech, Inc. · Tests: ACE1831, Lymphodepleting chemotherapy A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease NCT07190196Phase 395 sites📍 Fontana📍 Sacramento📍 San Jose Sanofi · Tests: Rilzabrutinib, Placebo, Glucocorticoid Institutional Registry of Rare Diseases NCT06573723n/a1 site📍 Buenos Aires Hospital Italiano de Buenos Aires A Prospective Cohort Study of IgG4RD in China NCT01670695n/a1 site📍 Beijing Peking Union Medical College Hospital Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease NCT06497387EARLY Phase 11 site📍 Wuhan Tongji Hospital · Tests: PRG-1801 Meir Medical Center Rheumatologic Biobank NCT03473912n/a1 site📍 Kfar Saba Meir Medical Center Treatment Strategies for IgG4-RD Patients With Superficial Organ Involvement NCT05789030NA1 site📍 Beijing Peking Union Medical College Hospital · Tests: glucocorticoid plus iguratimod, glucocorticoid plus leflunomide Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases NCT06285539Phase 26 sites📍 Amsterdam📍 Heerlen📍 Nijmegen UMC Utrecht · Tests: Filgotinib AYLo - AutoimmunitY and Loss of y NCT06696027n/a1 site📍 Bonn University of Bonn · Tests: Single nucleotide polymorphisms (SNP), 3'mRNA sequencing, Enzyme-linked immunosorbent assay (ELISA) and Legendplex… Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis NCT07536841n/a2 sites📍 Odesa📍 Odesa Military Medical Clinical Center of the Southern Region, Uk… · Tests: No intervention (observational study) Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms NCT05681975n/a1 site📍 Madrid Universidad Politecnica de Madrid · Tests: Food-specific Immunoglobulin G4 and/or Immunoglobulin E antibody reactions The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA. NCT07535554Phase 2, Phase 31 site📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: [18F]AlF-FAPI-74 PET/CT The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases NCT06285279Phase 11 site📍 Nanjing Nanjing University School of Medicine · Tests: FKC289
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy